The goal of the Accelerating Medicines Partnership (AMP) program is to unite the resources and expertise of the National Institutes of Health, private industry, and non-profit organizations to improve our understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes that will lead to the shared goal of accelerating new and effective therapies to patients. Managed by the Foundation for the National Institutes of Health with the interests of the collective scientific, medical research, and patient communities in mind, AMP projects work towards this goal by identifying clinically relevant disease targets, improving identification of patients most likely to respond to a particular treatment, and safely reducing the development timelines for life-saving therapies and improvements in patient outcomes.

About the Foundation for the National Institutes of Health: The Foundation for the National Institutes of Health (FNIH) builds public-private partnerships that connect leading biomedical scientists at the National Institutes of Health (NIH), life sciences companies, foundations, academia, and regulatory agencies, including the Food and Drug Administration and European Medicines Agency. Through team science, we solve complex health challenges and accelerate breakthroughs for patients, regardless of who they are or what health challenges they face. The FNIH accelerates new therapies, diagnostics, and potential cures; advances global health and equity in care; and celebrates and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visit fnih.org.